{
    "clinical_study": {
        "@rank": "78808", 
        "arm_group": [
            {
                "arm_group_label": "Alexandrite Laser for Skin Toning", 
                "arm_group_type": "Experimental", 
                "description": "755 nm Alexandrite Laser for Skin Toning"
            }, 
            {
                "arm_group_label": "Alexandrite Laser for Pigmented Lesions", 
                "arm_group_type": "Experimental", 
                "description": "755nm Alexandrite Laser for Epidermal Pigmented Lesions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess treatment for facial skin toning and removal of\n      epidermal pigmented lesions for Asian patients using the 755nm Alexandrite laser"
        }, 
        "brief_title": "Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Epidermal Pigmented Lesions", 
            "Skin Toning"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 85 years old\n\n          2. Has unwanted facial epidermal pigmented lesions or desires facial skin toning and\n             wishes to undergo laser treatments.\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits.\n\n          5. Has Fitzpatrick skin types III to IV.\n\n        Exclusion Criteria:\n\n          1. The subject is female and pregnant, has been pregnant within the last 3 months, is\n                currently breast feeding or planning a pregnancy during the study period.\n\n          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.\n\n          3. The subject has active or localized systemic infections\n\n          4. The subject has a coagulation disorder, or is currently using anti-coagulation\n             medication (including but not limited to heavy aspirin therapy {greater than 81 mg\n             per day}).\n\n          5. The subject has any condition which, in the investigator's opinion, would make it\n             unsafe for the subject to participate in this research study.\n\n          6. The subject is currently enrolled in an investigational drug or device trial, or has\n             received an investigational drug or been treated with an investigational device\n             within 3 months prior to entering this study.\n\n          7. The subject has used Accutane within 6 months prior to enrollment.\n\n          8. The subject has the need to be exposed to artificial tanning devices or excessive\n             sunlight during the trial.\n\n          9. The subject has had prior treatment with parenteral gold therapy (gold sodium\n             thiomalate).\n\n         10. The subject has a history of keloids or hypertrophic scarring.\n\n         11. The subject has evidence of compromised wound healing.\n\n         12. The subject has a history of squamous cell carcinoma or melanoma\n\n         13. The subject has a history of immunosuppression/immune deficiency disorders\n             (including HIV infection or AIDS) or use of immunosuppressive medications.\n\n         14. Allergic to topical lidocaine or topical steroids"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754246", 
            "org_study_id": "CYN12-PICO-PLASIAN"
        }, 
        "intervention": {
            "arm_group_label": [
                "Alexandrite Laser for Skin Toning", 
                "Alexandrite Laser for Pigmented Lesions"
            ], 
            "description": "755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types", 
            "intervention_name": "755nm Alexandrite Laser", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chestnut Hill", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02467"
                }, 
                "name": "Skin Care Physicians"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "2D Photography to assess progress pre and post treatment", 
            "measure": "Photographic Evaluation", 
            "safety_issue": "No", 
            "time_frame": "up to 4 months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754246"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}